Celltrion eyes biosim Remicade launch in the U.S. this year

Celltrion marketing CEO Stanley Hong has set his sights on shipping a less expensive version of rheumatoid arthritis drug Remicade to the U.S. in the third quarter, pending approval from the FDA. It could become the second big threat to a U.S. biologic blockbuster, after Novartis ($NVS) won approval for its Neupogen biosim last month. In February, the U.S. Patent Office rejected a patent that would have protected Remicade until 2018. Report

Suggested Articles

Takeda’s Alunbrig has arrived in previously untreated, ALK-positive NSCLC. But there’s plenty of competition waiting to greet it at the door.

Sanofi and Regeneron's blockbuster Dupixent is eyeing an approval in eosinophilic esophagitis after cutting patients' difficulty breathing.

Intercept Pharmaceuticals, eager to market its potential nonalcoholic steatohepatitis medicine obeticholic acid, will have to keep waiting.